New micro peptide HMBJ and use thereof
By discovering and verifying the new micropeptide HMBJ, the problem of lack of effective micropeptides for organ fibrosis in the existing technology is solved, and the significant inhibitory effect on organ fibrosis cells is achieved, providing new for the diagnosis and treatment of organ fibrosis. Ideas and drug development direction.
Patent Information
- Application Number
- PCT/CN2024/093256
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-21
AI Technical Summary
The lack of effective micropeptides for organ fibrosis in the prior art leads to diagnostic and therapeutic problems, and related research has not yet been explored in depth.
A new micropeptide HMBJ was discovered and verified, encoded by human lncRNA ENSG00000272654. Its endogenous encoding function was confirmed by gene editing, immunoprecipitation and LC-MS/MS, and its amino acid sequence was used to design nucleotide sequences. , construct recombinant vectors for the preparation of drugs for therapeutic or adjuvant treatment of organ fibrosis.
The novel micropeptide HMBJ significantly inhibits key indicators in the organ fibrosis cell model, such as the type I collagen α1 chain gene, transforming growth factor β1 and connective tissue growth factor, providing new potential drugs for the treatment of fibrotic diseases and extending treatment Score.
Smart Images

Figure CN2024093256_21112024_PF_FP_ABST
Abstract
Description
A novel micropeptide HMBJ and its application Technical Field
[0001] The present application belongs to the field of biomedicine, and specifically relates to a novel micropeptide HMBJ, lncRNA and / or ORF encoding the novel micropeptide HMBJ, and their application in diagnosis or auxiliary diagnosis, treatment or auxiliary treatment of fibrosis of various organs. Background Art
[0002] Long noncoding RNA (lncRNA) refers to a functional RNA molecule consisting of a stretch of more than 200 nucleotides that is believed to be incapable of being translated into protein. Existing studies have shown that lncRNA plays an important role in epigenetic regulation, cell cycle, and differentiation regulation, and is involved in major human health diseases, including cancer and degenerative neurological diseases. With the rapid development of molecular biology, computational biology, and deep sequencing technologies, a large number of previously unannotated non-canonical short open reading frames (ORFs) hidden within long noncoding RNAs actually have the function of encoding functional proteins. Micropeptides are a type of translation product encoded by short open reading frames (sORFs) with a length of 2 to 100 codons.
[0003] Organ fibrosis refers to a fibrotic disease that can occur in multiple organs. The main pathological changes are an increase in fibrous connective tissue and a decrease in parenchymal cells within the organ tissue. Persistent fibrotic lesions in organs can destroy organ structure and function, further leading to organ failure and malignant tumors. It is considered to be a tumor-like lesion between benign and malignant, and a serious threat to human health and life.
[0004] The discovery and study of organ fibrosis-related micropeptides is of great significance for developing novel and effective disease diagnosis and treatment, and can provide important reference and development value for exploring new application areas. However, there are currently no reports on micropeptides in the field of organ fibrosis research.
[0005] Summary of the Invention
[0006] 1. Purpose of the Invention
[0007] One of the purposes of the present application is to provide a lncRNA and a nucleotide sequence thereof, which is lowly expressed in organ fibrosis cells and / or tissues.
[0008] The second purpose of this application is to provide an ORF and its nucleotide sequence, wherein the ORF sequence is located in the above-mentioned lncRNA and can encode a novel micropeptide HMBJ.
[0009] The third purpose of the present application is to provide a novel micropeptide HMBJ and its amino acid sequence. The novel micropeptide HMBJ is a completely new endogenous human polypeptide discovered for the first time.
[0010] A fourth object of the present application is to provide a use of the aforementioned lncRNA in the preparation of a reagent for diagnosing or assisting in the diagnosis of organ fibrosis and / or the preparation of a drug for treating or assisting in the treatment of organ fibrosis.
[0011] The fifth object of the present application is to provide a use of the ORF sequence in the above-mentioned lncRNA in the preparation of a diagnostic or auxiliary diagnostic reagent for organ fibrosis and / or the preparation of a therapeutic or auxiliary therapeutic drug for organ fibrosis.
[0012] The sixth object of the present application is to provide the use of the novel micropeptide HMBJ or a nucleotide encoding the novel micropeptide HMBJ in the preparation of a drug for treating or assisting in the treatment of organ fibrosis.
[0013] 2. Technical solution
[0014] In order to achieve the above-mentioned invention objectives, the technical solutions adopted in this application are as follows:
[0015] The present application provides a lncRNA molecule ENSG00000272654, whose nucleotide sequence is shown in SEQ ID NO.1. By analyzing high-throughput sequencing data of multiple organ fibrosis, the applicant discovered for the first time that the lncRNA molecule ENSG00000272654 has an important relationship with organ fibrosis, specifically, it is lowly expressed in fibrotic cells and / or tissues of multiple organs. There are currently no related research reports.
[0016] The present application also provides the open reading frames (ORFs) of the above-mentioned lncRNA molecule ENSG00000272654, whose nucleotide sequence is shown in SEQ ID NO. 2. The applicant analyzed the translation characteristics of the open reading frame of the lncRNA molecule ENSG00000272654 and found that it has the potential to encode functional proteins. The applicant also performed endogenous coding verification using methods including gene editing, immunoprecipitation, and LC-MS / MS, confirming that the lncRNA molecule ENSG00000272654 has a coding sequence (ORF), and the sequence has not been reported anywhere.
[0017] The present application also provides a novel micropeptide HMBJ, whose amino acid sequence contains the sequence shown in SEQ ID NO.3, which is encoded by human lncRNA ENSG00000272654 and is a completely new endogenous human polypeptide discovered for the first time.
[0018] The present application also provides a nucleotide encoding the novel micropeptide HMBJ. The nucleotide sequence is not limited to the lncRNA molecule ENSG00000272654 or the ORF contained therein. Those skilled in the art know that the corresponding nucleotide sequence can be designed based on the amino acid sequence of the novel micropeptide HMBJ.
[0019] The present application also provides a recombinant vector, which includes the above-mentioned nucleotide sequence encoding the novel micropeptide HMBJ. The recombinant vector can be a plasmid, viral vector, or other vector known to those skilled in the art.
[0020] The present application also provides the use of the above-mentioned novel micropeptide HMBJ, nucleotides encoding the novel micropeptide HMBJ, and recombinant vectors in the preparation of drugs for treating or assisting in the treatment of organ fibrosis. The applicant has found through verification that the novel micropeptide HMBJ has a significant inhibitory effect on organ fibrosis cell models and can be used to treat or assist in the treatment of organ fibrosis.
[0021] Furthermore, the above-mentioned organ fibrosis includes liver fibrosis, kidney fibrosis and / or lung fibrosis, etc.
[0022] The present application also provides the use of the above-mentioned lncRNA molecule ENSG00000272654 and / or the ORF contained therein in the preparation of a reagent for diagnosing or assisting in the diagnosis of organ fibrosis.
[0023] Furthermore, the above-mentioned diagnostic or auxiliary diagnostic reagent for organ fibrosis includes primers for specifically amplifying the lncRNA molecule ENSG00000272654 or the ORF contained therein.
[0024] Furthermore, the above-mentioned specific primer pair contains the following nucleotide sequence:
[0025] F:CAAGGGATGGAGGCGAAACT;
[0026] R:CCACAGTGCTGGTCAAGTCA.
[0027] Furthermore, the above-mentioned organ fibrosis includes liver fibrosis, kidney fibrosis and / or lung fibrosis.
[0028] The present application also provides a pharmaceutical composition for treating or assisting in the treatment of organ fibrosis, which contains at least the novel micropeptide HMBJ, or the nucleotide encoding the novel micropeptide HMBJ, or the recombinant vector, and a pharmaceutically acceptable carrier.
[0029] The present application also provides a kit for diagnosing or assisting in the diagnosis of organ fibrosis, which includes primers for specifically amplifying the lncRNA molecule ENSG00000272654 or the ORF contained therein.
[0030] Furthermore, the above-mentioned specific primer pair contains the following nucleotide sequence:
[0031] F:CAAGGGATGGAGGCGAAACT;
[0032] R:CCACAGTGCTGGTCAAGTCA.
[0033] 3. Beneficial effects
[0034] Compared with the prior art, the present application has the following advantages:
[0035] (1) The present application provides a lncRNA and its nucleotide sequence. By analyzing multiple organ fibrosis sequencing data, it was found that the lncRNA molecule ENSG00000272654 is lowly expressed in organ fibrosis. A literature search found no relevant research reports. The lncRNA can be used for diagnosis or auxiliary diagnosis, treatment or auxiliary treatment of organ fibrosis, or for the preparation of diagnostic or auxiliary diagnosis, treatment or auxiliary treatment reagents for organ fibrosis.
[0036] (2) The present application provides a nucleotide sequence of an open reading frame of a lncRNA, which can encode a novel micropeptide HMBJ. After searching databases (BLAST, UniProt) and literature, no protein or polypeptide fragment with a homologous sequence to the micropeptide HMBJ was found. The nucleotide sequence can be used to encode and generate a novel micropeptide HMBJ, or to diagnose or assist in the diagnosis, treatment or auxiliary treatment of organ fibrosis, or to prepare a reagent for diagnosing or assisting in the diagnosis, treatment or auxiliary treatment of organ fibrosis.
[0037] (3) The present application provides a novel micropeptide HMBJ with a completely new amino acid sequence. After searching databases (BLAST, UniProt) and literature, no protein or polypeptide fragment with a homologous sequence to the micropeptide HMBJ was found. The novel micropeptide HMBJ consists of 71 amino acids. The synthetic peptide of the micropeptide HMBJ has a significant inhibitory effect on key indicators of human liver fibrosis, renal fibrosis and pulmonary fibrosis in vitro, including type I collagen α1 chain gene (Col1a1), transforming growth factor β1 (TGFβ1) and connective tissue growth factor (CTGF). The novel micropeptide HMBJ can also be used as a therapeutic drug for fibrosis of other organs, which greatly expands the therapeutic spectrum of the micropeptide and provides a new idea for the development of drugs for organ fibrosis.
[0038] (4) The present application uses a solid-phase synthesis method to obtain a synthetic peptide of a novel micropeptide HMBJ based on the amino acid sequence of the novel micropeptide HMBJ. The method mainly includes peptide synthesis, peptide purification, peptide purity detection and mass spectrometry identification. Three organ fibrosis cell models are constructed, for example, 10 nmol of recombinant human TGFβ1 (Peprotech) stimulating factor and different concentrations of synthetic peptides of the micropeptide HMBJ are added to human hepatic stellate cells LX-2, human non-small cell lung cancer cell line A549 and human renal proximal tubule cells HK2, respectively. After incubation for 24 hours, the total RNA of the collected cell samples is extracted using TRIzol reagent, and then the extracted total RNA is reverse transcribed using a reverse transcription reagent. The mRNA expression of genes Col1a1, TGFβ1 and CTGF in the three organ fibrosis cell models is detected using real-time fluorescence quantitative PCR. The results show that the synthetic peptide of the micropeptide HMBJ has a significant inhibitory effect on the three organ fibrosis cell models. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 is a volcano plot showing the low expression of ENSG00000272654 in organ fibrosis using differential analysis;
[0040] Figure 2 is a Sanger sequencing image of a monoclonal cell line containing a Flag tag inserted into the micropeptide HMBJ using a gene editing method;
[0041] Figure 3 shows the expression of the target band of micropeptide HMBJ detected by immunoprecipitation method;
[0042] FIG4 is a protein spectrum of the micropeptide HMBJ detected using the LC-MS / MS method;
[0043] FIG5 is a melting curve of primers for detecting the specificity of four organ fibrosis genes using the qPCR method;
[0044] FIG6 shows the detection of gene indicators in a human liver fibrosis cell model constructed using the qPCR method;
[0045] FIG7 is a qPCR method for detecting gene indicators in a human renal fibrosis cell model;
[0046] FIG8 is a qPCR method for detecting gene indicators in a human pulmonary fibrosis cell model;
[0047] FIG9 is a liquid phase result diagram of micropeptide HMBJ synthetic peptide;
[0048] FIG10 is a diagram showing the mass spectrometry results of the micropeptide HMBJ synthetic peptide;
[0049] FIG11 is a qPCR method used to detect the inhibitory effect of micropeptide HMBJ in a human liver fibrosis cell model;
[0050] FIG12 is a qPCR assay to detect the inhibitory effect of micropeptide HMBJ in a human renal fibrosis cell model;
[0051] FIG13 shows the inhibitory effect of micropeptide HMBJ in a human pulmonary fibrosis cell model detected by qPCR. DETAILED DESCRIPTION
[0052] The present application is further described below with reference to specific embodiments.
[0053] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs; the term "and / or" used herein includes any and all combinations of one or more of the associated listed items.
[0054] If the specific conditions are not specified in the examples, the experiments were carried out according to conventional conditions or those provided by the manufacturers. The reagents or instruments used, if the manufacturers are not specified, are all conventional products that can be purchased commercially.
[0055] As used herein, the term "about" is used to provide flexibility and imprecision associated with a given term, measurement, or value. One skilled in the art can readily determine the degree of flexibility for a particular variable.
[0056] As used herein, the term "at least one of" is intended to be synonymous with "one or more of." For example, "at least one of A, B, and C" explicitly includes only A, only B, only C, and combinations of each thereof.
[0057] Concentration, amount and other numerical data can be presented in range format in this article.Should be understood that such range format is only used for convenience and brevity, and should be flexibly interpreted as not only including the numerical value clearly described as range limit, but also including all independent numerical values or subranges encompassed within the scope, just as each numerical value and subrange are clearly described.For example, the numerical range of about 1 to about 4.5 should be interpreted as not only including the limit value of 1 to about 4.5 clearly described, but also including independent numerals (such as 2,3,4) and subranges (such as 1 to 3,2 to 4 etc.).The same principle is applicable to the scope of only narrating a numerical value, such as "less than about 4.5", which should be interpreted as including all above-mentioned values and scopes.In addition, no matter how the breadth of described scope or feature is, this explanation should be applicable.
[0058] In an embodiment, the method for validating endogenous encoding of micropeptides HMBJ includes gene editing, immunoprecipitation and LC-MS / MS, specifically including:
[0059] A gene editing approach was used to correctly insert a Flag tag at the genomic location of the micropeptide HMBJ;
[0060] Immunoprecipitation combined with chemiluminescence was used to observe the generation of target bands;
[0061] Protein profile of micropeptide HMBJ detected by LC-MS / MS method.
[0062] In the embodiment, the real-time fluorescence quantitative PCR method is used to detect gene indicators in the organ fibrosis cell model, specifically including:
[0063] Human hepatic stellate cells LX-2, human non-small cell lung cancer cell line A549, and human renal proximal tubule cells HK2 were plated and stimulated with different concentrations of recombinant human TGFβ1 (Peprotech).
[0064] After continuous stimulation for 24 h and 48 h, respectively, the mRNA expression of genes Col1a1 and α-SMA was detected by real-time fluorescence quantitative PCR to determine whether the cell model was successfully constructed.
[0065] In the embodiment, a novel micropeptide HMBJ was obtained by solid phase synthesis, and the quality inspection of the synthesized peptide was carried out, specifically including:
[0066] The peptide resin synthesis includes decapping with hexahydropyridine / N, N-dimethylformamide (DMF) decapping solution, washing the resin with DMF, then adding a condensing agent to fully react in a reactor, and finally washing the resin with DMF to clean the by-products;
[0067] Add lysis buffer to fully cleave the peptide, and use a sand core funnel to separate the resin and the peptide;
[0068] Anhydrous ether was added to precipitate the polypeptide, the supernatant was discarded by centrifugation, the polypeptide was washed with anhydrous ether, and the crude polypeptide was obtained by drying;
[0069] The crude peptide was dissolved in deionized water, filtered, and purified by semi-preparative HPLC;
[0070] The peptide purity was checked by analytical RP HPLC.
[0071] In an embodiment, the method of using real-time fluorescence quantitative PCR to detect the inhibitory effect of micropeptide HMBJ in a fibrotic cell model includes:
[0072] Human hepatic stellate cells LX-2, human non-small cell lung cancer cell line A549, or human renal proximal tubule cells HK2 were counted and plated;
[0073] Except for the blank group, 10 nmol of recombinant human TGFβ1 (Peprotech) stimulatory factor was added and the stimulation lasted for 24 h;
[0074] Total RNA from cell samples was extracted using TRIzol reagent, reverse transcribed using reverse transcription reagent, and then qPCR reaction was performed using qPCR premix solution;
[0075] Real-time fluorescence quantitative PCR instrument was used to detect the mRNA expression of genes Col1a1, TGFβ1 and CTGF.
[0076] Example 1
[0077] In this example, the expression level of gene ENSG00000272654 in fibrosis of various organs was analyzed.
[0078] The NCBI and ENA databases were searched using the keywords "fibrosis" and "Homo sapiens" and Aspera commands were used to batch download high-throughput sequencing data related to fibrosis in multiple organs, including human liver fibrosis and normal cell data (accession number: PRJNA638727), human liver fibrosis patient and healthy tissue data (accession number: PRJEB27201), human kidney fibrosis and normal cell data (accession number: GSE23338), and human lung fibrosis patient and healthy tissue data (accession number: PRJNA878759). The downloaded sequencing data were then processed and analyzed. Reads containing adapter sequences and low-quality bases were first filtered out using the Fastp software package (v0.18.0). The data were then aligned to human tRNA and rRNA sequences using the Bowtie software package (v1.3.0). Unsuccessful alignments were then aligned to the human reference genome (GRCh38.Ensembl98) using the HISAT2 software package (v2.2.1). Reads with a successful alignment rate greater than 90% were used for subsequent analysis. Genes and transcripts within the data were then assembled and quantified using the StringTie software package (v1.2.2). Differential gene expression analysis was then performed using the DESeq2 software package (v1.38.3). The results showed that gene ENSG00000272654 had a significant padj < 0.05 and a log2FoldChange < -1, indicating that this gene is underexpressed in fibrosis of multiple organs. The expression differences are shown in Figure 1.
[0079] Example 2
[0080] In this example, the coding capacity of the micropeptide HMBJ was endogenously tested, including gene editing, immunoprecipitation, and LC-MS / MS.
[0081] The gene sequence of ENSG00000272654 was downloaded from the Ensembl database, and the corresponding sgRNA plasmid and donor fragment containing the Flag tag were designed. These sgRNA plasmid and donor fragment were introduced into 293T cells using Lipo3000 lipofectamine. Fluorescence was observed 48 hours after transfection. The cells were harvested by trypsinization, centrifuged and the supernatant discarded, and resuspended in basal medium for flow cytometry sorting. The sorted cells were counted, plated for single clones, and Sanger sequenced to screen for single clones with the correct Flag tag insertion, as shown in Figure 2.
[0082] The cells were rinsed twice with PBS and harvested by trypsinization. The supernatant was discarded after centrifugation and the cell pellet was resuspended in RIPA lysis buffer. After lysis on ice for 30 minutes, the supernatant was collected by centrifugation at 12,000 g for 15 minutes. Flag antibody and agarose gel were added to form a protein-antibody-agarose gel complex. The gel was removed by centrifugation at 6,000 g for 1 minute, and 1× SDS loading buffer was added. The mixture was mixed and then denatured by boiling for 10 minutes. Total proteins were separated by 12% SDS-PAGE and transferred to a PVDF membrane. The membrane was then blocked with 5% nonfat dry milk for 3 hours at room temperature and washed five times with TBST for 10 minutes each. After incubation with the primary Flag antibody at 4°C overnight, the membrane was washed five times with TBST for 10 minutes each. The secondary antibody was incubated for 1 hour at room temperature and washed five times with TBST for 10 minutes each. The membrane was developed with ECL ultrasensitive chemiluminescence solution and the presence of the target band was detected using a Tannon imaging system. The results are shown in Figure 3.
[0083] In order to further demonstrate the coding ability of the micropeptide HMBJ, the SDS PAGE gel containing the target protein in the above step was stained with Coomassie Brilliant Blue, and the target band visible to the naked eye was cut out of the gel and detected by LC-MS / MS (liquid chromatography tandem quadrupole mass spectrometry) to obtain the mass spectrometry results of the target micropeptide, as shown in Figure 4.
[0084] After gene editing, immunoprecipitation and mass spectrometry detection, it was found that after the Flag tag was inserted into the genomic sequence of the target micropeptide, the target band and mass spectrometry peptide segment of the micropeptide HMBJ appeared, which fully proved that the new micropeptide HMBJ has the ability of endogenous encoding.
[0085] Example 3
[0086] In this example, real-time fluorescence quantitative PCR was used to detect gene indicators in three organ fibrosis cell models.
[0087] (1) Primer design
[0088] The key indicators of the organ fibrosis cell model include type I collagen α1 chain gene (Col1a1), transforming growth factor β1 (TGFβ1) and connective tissue growth factor (CTGF). Primer Premier 5.0 was used to design the corresponding primers, including Col1a1 upstream and downstream primers, TGFβ1 upstream and downstream primers, CTGF upstream and downstream primers, and α-SMA upstream and downstream primers. The total RNA of the collected cell samples was extracted according to the instructions of Life Invitrogen's TRIzol reagent. The purity and concentration of the extracted RNA were quantified using a NanoDrop 2000 ultra-micro spectrophotometer, and the integrity of the extracted RNA was ensured by agarose quality inspection. Reverse transcription reagent was used. After reverse transcription of the extracted total RNA using III RT SuperMix for qPCR (+gDNA wiper), qPCR reaction was performed using qPCR premix ChamQ SYBR qPCR Master Mix. The reaction system is as follows:
[0089] Table 1 qPCR reaction system
[0090] After mixing the above components, the following protocol was followed: pre-denaturation at 95°C for 30 seconds, followed by 50 cycles of 95°C for 10 seconds and 60°C for 30 seconds. After the qPCR reaction, the Cq values of each sample well were collected. The maximum error between the Cq values of the three replicate wells was ≤0.5 to ensure data accuracy. The melting curves of the designed primers were observed to confirm a single peak to determine reaction specificity, as shown in Figure 5.
[0091] (2) Model construction
[0092] Human hepatic stellate cells LX-2, human non-small cell lung cancer cell line A549, and human renal proximal tubule cells HK2 were cultured in a cell culture incubator at 37°C and 5% CO2 until the cell density reached above 80%. The cells were then collected by trypsin digestion, centrifuged, and the supernatant discarded. The cells were resuspended in complete medium and counted using a cell counter. The cell concentration was adjusted to 1.5×10 5 After culturing at a concentration of 100 cells / mL, the cells were seeded into six-well cell culture plates and cultured in a 37°C, 5% CO2 incubator. After 24 hours of cell culture, the culture medium was aspirated and different concentrations of recombinant human TGFβ1 (Peprotech) stimulator were added. After 24 and 48 hours of continuous stimulation, the mRNA expression of genes Col1a1 and α-SMA was detected by qPCR, as shown in Figures 6, 7, and 8.
[0093] Example 4
[0094] In this example, the micropeptide HMBJ was obtained by solid phase synthesis, and the quality of the synthesized micropeptide was tested.
[0095] In this embodiment, the peptide solid phase synthesis method is used to synthesize the micropeptide HMBJ, the synthesized micropeptide HMBJ is separated and purified by preparative HPLC, and the purity of the micropeptide HMBJ is determined by analytical RP HPLC. The peptide solid phase synthesis method uses Fmoc-Thr-wang resin as the starting material, and then uses protected amino acids to couple to the last amino acid of the target sequence in sequence. After the coupling work is completed, the crude polypeptide is obtained by sufficient washing, cleavage, and post-treatment. After the crude product is dissolved, it is purified, concentrated, and freeze-dried using preparative high-performance liquid phase to obtain a pure polypeptide. The specific reaction steps are as follows:
[0096] (1) Peptide resin synthesis
[0097] Weigh 1 mmol of Fmoc-Thr-wang resin, pour it into a glass sand core reaction column, and add 20 ml of CH2Cl2 to fully swell the resin.
[0098] a. Decapping: Add 20 ml of 20% hexahydropyridine / N, N-dimethylformamide (DMF) decapping solution, allow to react for a period of time, drain the decapping solution, wash once with DMF, and then add 20 ml of decapping solution to remove the Fmoc protecting group.
[0099] b. Washing: Drain the decapping solution and wash the resin with DMF to fully remove the by-products;
[0100] c. Condensation: The protected amino acid and activator for coupling are dissolved in DMF and a condensing agent and reacted fully in a reactor;
[0101] d. Washing: Drain the reaction solution and thoroughly wash the resin with DMF to remove by-products.
[0102] (2) Cracking
[0103] The drained resin was placed in a conical flask, and a lysis solution was added to fully lyse the combined polypeptide. The resin and polypeptide were separated using a sand core funnel. The composition of the lysis solution and the volume composition of each component were: trifluoroacetic acid: phenol: water: thioanisole: EDT = 90:3:3:2:2.
[0104] (3) Post-processing
[0105] The lysate was added to anhydrous ether after ice bath, and slowly stirred to precipitate the polypeptide. After centrifugation and discarding the supernatant, the polypeptide was washed with anhydrous ether and dried to obtain the crude polypeptide.
[0106] (4) Purification
[0107] a. Dissolution: Dissolve the crude polypeptide in deionized water and filter through a 0.45 μm pore size filter membrane.
[0108] b. Preparation: Purification was performed by semi-preparative HPLC, mobile phase: A was 0.1% TFA (acetonitrile), B was 0.1% TFA (water), the purification system is as follows:
[0109] Table 2 Peptide purification system
[0110] The solution at an ultraviolet wavelength of 220 nm was collected, and the molecular weight was confirmed to be consistent with the theoretical value by MS. The purity of the solution was greater than 95% by HPLC analysis. The qualified solution was concentrated under reduced pressure at 37°C using a rotary evaporator to remove the organic solvent, placed in a freeze-drying plate and frozen at -80°C, and then freeze-dried using a freeze dryer to obtain the pure polypeptide.
[0111] (5) Purity testing
[0112] The purified product was collected after lyophilization and tested for peptide purity by analytical RP HPLC. The analysis conditions were: mobile phase: 0.1% TFA (acetonitrile), 0.1% TFA (water); sample volume: 10 μL. The specific reaction system is as follows:
[0113] Table 3 Purity detection system
[0114] The synthesized peptide was analyzed by reversed-phase liquid chromatography for purity identification. The results showed that the purity of the prepared micropeptide HMBJ reached 95.86%, which is greater than 95%, as shown in Figures 9 and 10, and met the requirements of subsequent experiments. The specific information is as follows:
[0115] Table 4 Purity test results
[0116] Example 5
[0117] In this example, the inhibitory effect of the micropeptide HMBJ on a human liver fibrosis cell model was detected. Human hepatic stellate cells LX-2 were cultured in a cell culture incubator at 37°C and 5% CO2 until the cell density reached 80%. The cells were then collected by trypsin digestion, centrifuged and the supernatant discarded. The cells were resuspended in complete culture medium and counted using a cell counter. The cell concentration was adjusted to 1.5×10 5 / mL, and then inoculated into a six-well cell culture plate and placed in a cell culture incubator at 37°C and 5% CO2 for further culture. After 24 hours of cell culture, the culture medium was aspirated, and 2‰ DMSO solvent was added as a negative control and 20μmol of hydroxynidone was added as a positive control. The remaining groups were added with equal proportions of 40μmol, 10μmol, 2.5μmol, 625nmol and 156nmol of synthetic peptide HMBJ as the drug-dosing group. Half an hour later, except for the blank control, 10nmol of recombinant human TGFβ1 (Peprotech) stimulating factor was added to the remaining groups. After 24 hours of continuous stimulation, the mRNA expression of genes Col1a1, TGFβ1 and CTGF was detected, as shown in Figure 11.
[0118] Example 6
[0119] In this example, the inhibitory effect of the micropeptide HMBJ on a human renal fibrosis cell model was detected.
[0120] Human renal proximal tubular HK2 cells were cultured in a cell culture incubator at 37°C and 5% CO2 until the cell density was above 80%. The cells were collected by trypsin digestion, centrifuged and the supernatant was discarded. The cells were resuspended in complete culture medium and counted using a cell counter. The cell concentration was adjusted to 1.5×10 5 / mL, and then inoculated into a six-well cell culture plate and placed in a cell culture incubator at 37°C and 5% CO2 for further culture. After 24 hours of cell culture, the culture medium was aspirated, and 2‰ DMSO solvent was added as a negative control and 20μmol of hydroxynidone was added as a positive control. The remaining groups were added with equal proportions of 40μmol, 10μmol, 2.5μmol, 625nmol and 156nmol of synthetic peptide HMBJ as the drug-dosing group. Half an hour later, except for the blank control, 10nmol of recombinant human TGFβ1 (Peprotech) stimulating factor was added to the remaining groups. After 24 hours of continuous stimulation, the mRNA expression of genes Col1a1, TGFβ1 and CTGF was detected, as shown in Figure 12.
[0121] Example 7
[0122] In this example, the inhibitory effect of the micropeptide HMBJ on a human pulmonary fibrosis cell model was detected.
[0123] Human non-small cell lung cancer cell line A549 was cultured in a cell culture incubator at 37°C and 5% CO2 until the cell density was above 80%. The cells were collected by trypsin digestion, centrifuged and the supernatant was discarded. The cells were resuspended in complete medium and counted using a cell counter. The cell concentration was adjusted to 1.5×10 5 / mL, and then inoculated into a six-well cell culture plate and placed in a cell culture incubator at 37°C and 5% CO2 for further culture. After 24 hours of cell culture, the culture medium was aspirated, and 2‰ DMSO solvent was added as a negative control and 2μmol of Nintedanib was added as a positive control. The remaining groups were added with equal proportions of 40μmol, 10μmol, 2.5μmol, 625nmol and 156nmol of synthetic peptide HMBJ as the drug-dosing group. Half an hour later, except for the blank control, 10nmol of recombinant human TGFβ1 (Peprotech) stimulating factor was added to the remaining groups. After 24 hours of continuous stimulation, the mRNA expression of genes Col1a1, TGFβ1 and CTGF was detected, as shown in Figure 13.
Claims
1. A novel micropeptide HMBJ, characterized in that: The novel micropeptide HMBJ contains the amino acid sequence shown in SEQ ID NO.
3.
2. A nucleotide, characterized in that The nucleotide encodes a novel micropeptide HMBJ as described in claim 1.
3. A nucleotide according to claim 2, characterized in that The nucleotide sequence includes the lncRNA molecule ENSG00000272654 and / or the ORF contained therein. The nucleotide sequence of the lncRNA molecule ENSG00000272654 is shown in SEQ ID NO.1; the nucleotide sequence of the ORF contained in the lncRNA molecule ENSG00000272654 is shown in SEQ ID NO.
2.
4. Use of a nucleotide according to claim 3 in the preparation of a reagent for diagnosing or assisting in the diagnosis of organ fibrosis, wherein the organ fibrosis includes liver fibrosis, kidney fibrosis and / or lung fibrosis.
5. Use of a nucleotide according to claim 4 in preparing a reagent for diagnosing or assisting in diagnosing organ fibrosis, characterized in that: The diagnostic or auxiliary diagnostic reagent for organ fibrosis includes primers for specifically amplifying the lncRNA molecule ENSG00000272654 or the ORF contained therein.
6. A recombinant vector, characterized in that: The recombinant vector contains the nucleotide according to claim 2 or 3.
7. Use of a novel micropeptide HMBJ according to claim 1, a nucleotide according to claim 2 or 3, or a recombinant vector according to claim 6 in the preparation of a drug for treating or assisting in treating organ fibrosis, wherein the organ fibrosis includes liver fibrosis, kidney fibrosis and / or lung fibrosis.
8. A pharmaceutical composition for treating or assisting in treating organ fibrosis, characterized in that: The pharmaceutical composition contains at least the novel micropeptide HMBJ according to claim 1, or the nucleotide according to claim 2 or 3, or the recombinant vector according to claim 6, and a pharmaceutically acceptable carrier.
9. A kit for diagnosing or assisting in the diagnosis of organ fibrosis, characterized in that: The kit contains a specific primer pair for the nucleotide sequence of claim 3.
10. A kit for diagnosing or assisting in the diagnosis of organ fibrosis according to claim 9, characterized in that: The specific primer pair contains the following nucleotide sequences: F: CAAGGGATGGAGGCGAAACT; R: CCACAGTGCTGGTCAAGTCA.
Citation Information
Patent Citations
Micropeptides and use of same for modulating gene expression
CN105874083A
Micropeptides and uses thereof
CN112088163A
Novel micro-peptide HMMW and application thereof
CN112442116A
Novel micropeptide screened based on pan cancer expression profile and application of novel micropeptide
CN113429464A
Methods for altering the microbiome influenced by roots of a plant using micropeptides
WO2022207919A1
